KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Other Operating Expenses (2023 - 2025)

Biocryst Pharmaceuticals' Other Operating Expenses history spans 7 years, with the latest figure at $9.5 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 56.25% year-over-year to $9.5 million; the TTM value through Dec 2025 reached $19.1 million, up 55.47%, while the annual FY2025 figure was $19.1 million, 55.47% up from the prior year.
  • Other Operating Expenses reached $9.5 million in Q4 2025 per BCRX's latest filing, up from $2.2 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $9.5 million in Q4 2025 to a low of $1.3 million in Q1 2024.
  • Average Other Operating Expenses over 3 years is $3.8 million, with a median of $2.8 million recorded in 2025.
  • The largest YoY upside for Other Operating Expenses was 261.11% in 2025 against a maximum downside of 31.89% in 2025.
  • A 3-year view of Other Operating Expenses shows it stood at $2.6 million in 2023, then surged by 133.22% to $6.1 million in 2024, then surged by 56.25% to $9.5 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Other Operating Expenses are $9.5 million (Q4 2025), $2.2 million (Q3 2025), and $2.8 million (Q2 2025).